Do Kim
Stock Analyst at Piper Sandler
(2.05)
# 2,899
Out of 4,876 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $39.80 | +58.29% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $14.77 | +211.44% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $441.30 | -32.93% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $110.67 | +1.20% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $20.61 | +322.13% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.39 | +862.34% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $19.48 | +2.67% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $9.33 | +360.88% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $43.67 | -26.72% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.61 | +509.42% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $35.81 | -46.94% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.93 | +729.02% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $322.83 | -42.69% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $5.89 | +15,180.14% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $52.21 | -32.96% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.04 | +1,823.08% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $39.80
Upside: +58.29%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $14.77
Upside: +211.44%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $441.30
Upside: -32.93%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $110.67
Upside: +1.20%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $20.61
Upside: +322.13%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.39
Upside: +862.34%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $19.48
Upside: +2.67%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $9.33
Upside: +360.88%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $43.67
Upside: -26.72%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.61
Upside: +509.42%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $35.81
Upside: -46.94%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $1.93
Upside: +729.02%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $322.83
Upside: -42.69%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $5.89
Upside: +15,180.14%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $52.21
Upside: -32.96%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.04
Upside: +1,823.08%